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ABSTRACT 
 
Variation in the human leukocyte antigen (HLA) genes accounts for one-half of the genetic risk 
in type 1 diabetes (T1D). Amino acid changes in the HLA-DR and -DQ molecules mediate most 
of the risk; but extensive linkage disequilibrium complicates localization of independent effects. 
Using 18,832 case-control samples, we localized the signal to three amino acid positions in 
HLA-DQ and -DR. DQβ1 position 57 (previously known, p=10–1355) alone explained 15.2% of the 
total phenotypic variance. Independent effects at DRβ1 positions 13 (p=10–721) and 71 (p=10–95) 
increased the proportion to 26.9%. The three positions together explained 90% of the 
phenotypic variance in HLA-DRB1-DQA1-DQB1. Additionally, we observed significant 
interactions in 11 of 21 pairs of common HLA-DRB1-DQA1-DQB1 haplotypes (p=1.6x10–64). 
DRβ1 positions 13 and 71 implicate the P4 pocket in the antigen-binding groove, thus pointing 
to another critical protein structure for T1D risk, in addition to the DQ P9 pocket. 
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INTRODUCTION 
Type 1 diabetes (T1D) is a highly heritable autoimmune disease that results from T cell-
mediated destruction of the insulin-producing pancreatic β cells. The worldwide incidence of 
T1D ranges from 0.1 per 100,000 persons in China to >36 per 100,000 in parts of Europe, and 
has been steadily increasing1. Many autoimmune diseases, including T1D, rheumatoid arthritis 
(RA), celiac disease, and multiple sclerosis, have more genetic risk attributed to variants in the 
human leukocyte antigen (HLA) genes within the major histocompatibility complex (MHC) region 
located on 6p21.32-4 than any other locus. HLA genes encode surface proteins that display 
antigenic peptides to effector immune cells in order to regulate self-tolerance and downstream 
immune responses. Autoimmune risk conferred by HLA is likely the result of variation in amino 
acid residues at specific positions within the antigen-binding grooves, which may then alter the 
repertoire of presented peptides5-8. In T1D, the largest allelic associations are in HLA-DRB1-
DQA1-DQB1, a three-gene “superlocus” that encodes HLA-DR and -DQ proteins9,10; additional 
associations have been identified in the genes encoding HLA-A, -B, -C, and -DP11-14.  
 
Todd et al. initially identified strong T1D risk conferred by non-aspartate residues at position 57 
of HLA-DQβ115. However, this amino acid position alone does not fully explain the HLA risk in 
T1D. Subsequently, many amino acid positions in DQβ1 and DRβ1 have been hypothesized to 
modify risk16; but extensive linkage disequilibrium (LD) spanning the 4 Mb MHC region makes it 
challenging to pinpoint the specific risk variants. In addition, certain heterozygous genotypes 
confer the greatest disease risk 13,17-19, consistent with synergistic interactions between classical 
HLA alleles. Despite evidence of non-additive effects within the MHC on autoimmune disease 
risk, interactions have not been comprehensively examined in T1D. If the risk-conferring amino 
acid positions and their interactions were understood, mechanistic investigation of how 
autoantigens interact with HLA proteins could become feasible. In this study, we utilized recently 
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established accurate genotype imputation methods to examine a large case-control sample, and 
rigorously identified independent amino acid positions as well as interactions within the HLA that 
account for T1D risk (see Supplementary Figure 1 for a schematic of analyses). 
  
RESULTS 
HLA Imputation and association testing 
We fine-mapped the MHC region in a collection of 8,095 T1D cases and 10,737 controls 
genotyped with the ImmunoChip array, provided by the Type 1 Diabetes Genetics Consortium 
(T1DGC)20-22. The dataset included (1) case-control samples collected in the United Kingdom 
(UK), and (2) a pseudocase-control set derived from European families (Eur) (see Online 
Methods in and Supplementary Table 1). Using a set of 5,225 individuals with classical HLA 
typing as a reference22, we accurately imputed 8,617 binary markers (with minor allele 
frequency > 0.05%) between ~29 Mb and ~33 Mb (the 4 Mb classical MHC region) on 
chromosome 6p21.3 with SNP2HLA software21. The resulting data included 7,242 SNPs, 260 2- 
and 4-digit classical alleles, and amino acid residues at 399 positions in eight HLA genes (HLA-
A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, and -DPB1) with high imputation quality (INFO score 
> 0.96; see Supplementary Table 2 for the list of variants and imputation quality). We have 
previously independently benchmarked the imputation strategy employed in this study for 
accuracy, using a set of 918 samples with gold-standard HLA typing data. Starting with SNPs 
from the ImmunoChip genotyping platform and using the T1DGC reference panel, SNP2HLA 
obtained an accuracy of 98.4%, 96.7% and 99.3% for all 2-digit alleles, 4-digit alleles, and 
amino acid polymorphisms, respectively21. 
 
To test for T1D association of a given variant, we used a logistic regression model, assuming 
the log-odds of disease to be proportional to the allelic dosage of the variant. We also included 
covariates to adjust for sex and region of origin (see Supplementary Note and Supplementary 
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Figure 2). As expected, the strongest associations with T1D were within the HLA-DRB1-DQA1-
DQB1 locus. We confirmed that the leading risk variant was the presence of alanine at DQβ1 
position 57 (DQβ1#57, p=10–1090, OR=5.17; Figure 1A, Supplementary Table 2). In contrast, 
the single most significantly associated classical allele was DQB1*03:02 (p=10–840), which has 
an alanine at DQβ1#57, but was much more weakly associated than the amino acid residue 
itself. Table 1 lists common classical alleles tagged by each residue at key amino acid 
positions. 
 
Three amino acid positions independently drive T1D risk  
Given the strength and complexity of the association within HLA-DRB1-DQB1-DQA1, we aimed 
to first identify independent effects in this locus before examining the rest of the MHC. We 
assessed the significance of multi-allelic amino acid positions using conditional analysis by 
forward-search (see Online Methods). Unsurprisingly, the most strongly associated position 
with T1D was DQβ1#57 (omnibus p=10–1355, Figure 2, Tables S3 and S4A). At this position, 
alanine conferred the strongest risk (OR=5.17; Figure 3), while the most common residue in 
controls, aspartic acid, was the most protective (OR=0.16). Conditioning on DQβ1#57, the 
second independent association was at DRβ1#13 (omnibus p=10–721, Figure 2). At this position, 
histidine (OR=3.64) and serine (OR=1.28) conferred the strongest risk, while arginine (OR=0.08) 
and tyrosine  (OR=0.28) were protective (Figure 3, Supplementary Table 4A). The DRβ1#71 
position was the third independently associated signal (omnibus p=10–95, Figure 2); lysine 
conferred strong risk (OR=4.70), and alanine was strongly protective (OR=0.04, Figure 3, 
Supplementary Table 4A). We note that at these positions, the risk-conferring amino acid 
residues indeed tag the DR3 and DR4 haplotypes, which confer the strongest risk among 
haplotypes. Histidine at position 13 tags DRB1*04:01 and 04:04, while serine tags DRB1*03:01. 
Lysine at position 71 tags both DRB1*03:01 and DRB1*04:01. Tables 1 and S6 list the classical 
alleles tagged by residues at each key amino acid position, and multivariate odds ratios of 
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haplotypes defined by these positions. 
 
Given the reported deviation from log-scale additivity of T1D risk effects in the HLA19,23, we 
wanted to confirm that their contribution did not alter the risk-driving amino acid positions. By 
repeating the forward-search analysis while including non-additive terms in the regression 
model, we confirmed that DQβ1#57, DRβ1#13, and DRβ1#71 were the top three independent 
signals under the non-additive model as well as the additive model (see Supplementary Note 
and Supplementary Figure 3).  
 
We exhaustively tested all possible combinations of two, three, and four amino acid positions in 
HLA-DRB1-DQA1-DQB1, and confirmed that DQβ1#57, DRβ1#13, and DRβ1#71 were the best 
of all 457,450 combinations of three amino acids (p=10–2161; see Supplementary Table 7). 
Conditioning on these three positions, more than 80 other positions and classical alleles 
remained highly significant (p < 10–8; see Supplementary Table 4B and S4C), suggesting the 
presence of other independent associations. DQβ1#–18 (located within the signal peptide) 
emerged as the fourth most significant association (p=10–40) through forward-search; however, 
in the exhaustive test, many other combinations of four amino acid positions exceeded the 
goodness-of-fit of DQβ1#57/DRβ1#13/DRβ1#71/DQβ1#–18 (Supplementary Table 7). 
Therefore, we do not report subsequent positions that emerged through conditional analysis, as 
we could not confidently claim additional positions as independent drivers of T1D risk.  
 
We wanted to confirm that these three amino acid positions were not simply tagging effects of 
specific haplotypes. To this end, we performed a permutation analysis in which we randomly 
reassigned amino acid sequences corresponding to each HLA-DRB1, -DQB1, and -DQA1 
classical allele, and retested for the best amino acid positions (see Online Methods). This 
approach preserved haplotypic associations; if certain amino acids were tagging associated 
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haplotypes, equally significant amino acid associations would be found in the permuted data. 
After 10,000 permutations, no combination of permuted amino acids resulted in a model that 
equaled or exceeded the goodness-of-fit of DQβ1#57/DRβ1#13/DRβ1#71 in our data, as 
measured by either deviance or p-value (see Supplementary Figure 4).  
 
Finally, to ensure that the observed effects were not the results of heterogeneity between the 
UK and the European subsets, we separately repeated the association analysis in the two 
subsets. The two sets yielded highly correlated effect sizes for all binary markers (Pearson 
r=0.952, Supplementary Figure 5A), as well as for all haplotypes formed by residues at 
DQβ1#57, DRβ1#13, and DRβ1#71 (Pearson r=0.989, Supplementary Figure 5B). 
 
Key amino acids are located in the peptide-binding grooves 
DQβ1#57, DRβ1#13, and DRβ1#71 are each located in the peptide-binding grooves of the 
respective HLA molecule (Figure 4). DRβ1#13 and #71 line the P4 pocket of HLA-DR, which 
has been previously implicated in seropositive RA2, seronegative RA24, and follicular 
lymphoma25. While DRβ1#13 and DRβ1#71 are both involved in T1D and RA, the effects of 
individual residues at each position are discordant between the diseases (p<10–232; see 
Supplementary Figure 6 and Online Methods).  
 
The three amino acid positions explain over 90% of T1D phenotypic variance in HLA-
DRB1-DQA1-DQB1 
We quantified the proportion of phenotypic variance captured by the three amino acid positions 
using the liability threshold model26 (see Supplementary Note). Assuming a T1D prevalence of 
0.4%27, the additive effects of all 67 haplotypes in HLA-DRB1-DQA1-DQB1 explained 29.6% of 
the total phenotypic variance (Supplementary Table 6). DQβ1#57 alone explained 15.2% of 
the total variance, while the addition DRβ1#13, and DRβ1#71 increased the proportion 
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explained by 11.7%. Therefore, these three amino acid positions together capture 26.9% of the 
total variance, accounting for over 90% of the T1D-HLA association in this locus (Figure 5). 
 
Independent HLA associations in HLA-B, -DPB1, and -A 
We then sought to identify HLA associations to T1D independent of those in HLA-DRB1-DQA1-
DQB1. We conservatively conditioned on all HLA-DRB1, DQA1, and DQB1 4-digit classical 
alleles to eliminate all effects at these loci. We observed the next strongest association across 
the MHC in HLA-B, where the classical allele HLA-B*39:06 was the most significant signal 
(OR=6.64, p=10–75, Figure 1B, Supplementary Table 5A)11. After adjusting for B*39:06, other 
classical alleles and amino acid positions in HLA-B remained significantly associated, including 
B*18:01 and B*50:01. Upon additionally adjusting for all HLA–B alleles, HLA-DPB1*04:02 was 
the next strongest independent signal (OR=0.47, p < 10–55, Figure 1C), which is nearly perfectly 
tagged by methionine at amino acid position 178. Conditioning on DPB1*04:02, additional 
associations were present in HLA-DPB1, including position 65 and DPB1*01:01 
(Supplementary Table 5B). After conditioning on DPB1 alleles as well, we observed 
independent effects in HLA-A led by position 62 (p=10–45, Figure 1D); additional signals 
included A*03 and A*24:02 (Supplementary Table 5C). We observed no independent 
association with T1D in HLA-C or -DPA1 (Figure 1E). The independent effects of all haplotypes 
in HLA-B, -DPB1, and -A together explained ~4% of the total phenotypic variance. The total 
T1D risk variance explained by additive effects in the eight HLA genes was ~34%, consistent 
with the estimates by Speed et al.28. 
 
HLA haplotypic interaction effects are common in T1D 
The previously observed excess risk of T1D in HLA-DR3/DR4 (DRB1*03:01-DQA1*05:01-
DQB1*02:01/DRB1*04:xx-DQA1*03:01-DQB1*03:02) heterozygotes may represent a 
synergistic interaction between two distinct alleles23. Here, we conducted an unbiased search 
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for interactions among all haplotypes within the HLA-DRB1-DQA1-DQB1 locus (see Online 
Methods). As interactions cannot be observed reliably with rare genotypes, we focused this 
analysis on the seven HLA-DRB1-DQA1-DQB1 haplotypes with frequencies > 5%; all of these 
haplotypes had very imputation accuracies (INFO score > 0.94; see Supplementary Table 8 
and Supplementary Note).  
 
We tested for interactions between all possible pairs of haplotypes using a global multivariate 
regression model that included 21 interactive terms as well as seven additive terms. The 
inclusion of interactions in the model produced a statistically significant improvement in fit over 
the additive model (p=1.6x10–64). Of the 21 potential interactions, 11 were significant after 
correcting for 21 tests (p<0.05/21=2.4x10–3; Figure 6, Table 2, Supplementary Table 9). 
Consistent with previous reports9,19, we observed a significant interaction between the HLA-DR3 
haplotype (DRB1*03:01-DQA1*05:01-DQB1*02:01) and a DR4 haplotype (DRB1*04:01-
DQA1*03:01-DQB1*03:02) (p=1.2 x 10–5). This interaction resulted in an odds ratio of 30.42, 
compared to an expected odds ratio of 15.51 due to only additive contributions. Likewise, we 
confirmed an independent interaction between DRB1*03:01-DQA1*05:01-DQB1*02:01and 
DRB1*04:04-DQA1*03:01-DQB1*03:02 (p=1.9x10–4).  
 
We observed many other significant haplotypic interactions beyond the well-studied DR3/DR4 
heterozygote effect (Table 2 and Supplementary Table 9). Most interactions increased T1D 
risk. For example, the combination of DRB1*04:01-DQA1*03:01*DQB1*03:02 and DRB1*07:01-
DQA1*02:01-DQB1*02:02 dramatically increased risk by 5.09-fold (beyond the risk predicted by 
the additive model). Other pairs significantly reduced risk. Notably, while DRB1*04:01-
DQA1*03:01-DQB1*03:02 and DRB1*04:04-DQA1*03:01-DQB1*03:02 each conferred risk, the 
heterozygote combination elicited a 3-fold reduction from the expected risk. Since we restricted 
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our analysis to haplotypes with at least 5% allele frequency, other interactive effects are likely 
present but unobserved19. 
 
Interaction effects are mediated by DQβ1#57 and DRβ1#13 
The HLA-DQ α/β trans heterodimer formed by proteins encoded by DQA1*05:01 and 
DQB1*03:02 may confer a particularly high risk for individuals with the DR3/DR4 genotype due 
to its unique antigen binding properties29. In order to identify the possible drivers of this 
haplotypic interaction, we tested pairwise interactions among the HLA-DRB1, -DQA1, and -
DQB1 4-digit alleles. We observed a significant interaction between DQA1*05:01 and 
DQB1*03:02 (p=1.71x10–25). However, due to high LD across the locus, several pairs of 
classical alleles (including DQB1*02:01/DQB1*03:02 and DRB1*03:01/DQB1*03:02, 
Supplementary Table 10) achieved similarly significant p-values. Therefore, while our model 
was consistent with a risk-conferring interaction between DQA1*05:01 and DQB1*03:02, we 
could not eliminate the possibility that interactions between other alleles within the two 
haplotypes are driving this specific interaction. 
 
We next assessed whether these haplotypic interactions could be explained by amino acid 
positions. We exhaustively tested for all pairwise interactions among amino acid residues in 
HLA-DRB1-DQA1-DQB1, again limiting the analysis to residues with at least 5% frequency. Of 
the 3,773 pairs of amino acid positions tested, we observed that interactions between DQβ1#57 
and DRβ1#13 yielded the largest improvement over the additive model (Supplementary Table 
11). We note that two other pairs of amino acid positions achieved similarly significant p-values. 
These analyses suggest that the same amino acid positions that explain the greatest proportion 
of the additive risk may also be the positions that mediate interactive effects within this locus. 
 
DISCUSSION 
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Fine-mapping the MHC locus in T1D demonstrates that amino acid polymorphisms at DQβ1#57, 
DRβ1#13, and DRβ1#71 independently modulate T1D risk, and capture over 90% of the 
phenotypic variance explained by the HLA-DRB1-DQA1-DQB1 locus (and 80% of the variance 
explained by the entire MHC). Previous studies have suggested that other amino acid positions 
within the HLA class II molecules confer T1D risk; for example, DRβ1#86, DRβ1#74, and 
DRβ1#57 in the P1, P4, and P9 pockets, respectively16. While our analysis highlights the top 
three amino acid positions as the main contributors of T1D risk, there is also evidence of other 
allelic effects within the HLA-DRB1-DQA1-DQB1 locus; however their relative effect sizes were 
very modest compared to the three leading positions identified. We note that our results are 
derived from cases and controls from a relatively homogeneous population (the United 
Kingdom), and our ability to interrogate rare alleles in this population may be limited. For 
instance, HLA-DRB1*04:03, a common protective allele in the Sardinian population highlighted 
by Cucca et al.16, is rare in this dataset with an allele frequency of 0.3%. As such, the observed 
effect of amino acid positions which best define this allele (DRβ1#74 and #86) may have been 
less pronounced than what might be observed in a more diverse dataset. Additional variants 
may be conclusively identified in the future with increased sample size. Finally, although coding 
variants contribute to the majority of the phenotypic variance in T1D, there is the possibility that 
there are other mechanisms, such as gene and protein expression, that further modulate 
susceptibility30,31. 
 
Beyond the previously described HLA-DR3/DR4 interactions, we find nine additional pairwise 
interactions between HLA haplotypes that contribute to T1D risk, suggesting that non-additive 
effects are common within this locus. Notably, we showed that amino acid positions in DQβ1#57 
and DRβ1#13 were the strongest contributors to both additive and interactive risk effects. 
Interestingly, the two strongest interacting amino acid positions are in separate HLA molecules 
(DQ and DR, respectively). HLA-DQA1, which is in strong LD to HLA-DRB1 and HLA-DQB1, 
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appears to play a minimal role in modulating T1D risk. This suggests that the interactive effects 
are possibly due to the alteration in antigen-presentation repertoire created by the combination 
of different HLA molecules, rather than the consequence of specific DQα/β heterodimers with 
particular structural features that confer extreme binding affinities.  
 
The HLA amino acid variants identified in our study may mediate recognition of one or more 
autoantigens and cause autoimmunity through different mechanisms. In particular, our findings 
implicate the HLA-DR P4 pocket in T1D in addition to the known role of the HLA-DQ P9 pocket; 
this is the first instance to our knowledge where the DR P4 pocket plays an important but 
secondary role to a different locus (DQβ1#57). The DR P4 pocket has been shown to play 
primary roles in other autoimmune diseases. For example, in RA, the risk-conferring amino acid 
residues in P4 likely facilitate the binding of citrullinated peptides7. In T1D, the anti-islet 
autoantibody reactivity in patients’ sera is largely accounted for by four autoantigens: 
preproinsulin, glutamate decarboxylase (GAD), islet antigen 2 (IA-2), and ZnT8; although the 
identification of specific peptides that affect autoreactivity is still work in progress8,32-37. Cucca et 
al. implicated signal peptide sequences of preproinsulin as potentially important in T1D, by 
modeling the associations of HLA class II alleles and their polymorphic amino acid positions 
with structural features of the peptide-binding pockets16. The discovery of critical variants that 
drive T1D risk enable future functional investigations. Synthesis of HLA molecules containing 
single-residue alterations at risk-modulating positions may reveal their effects on the 
physicochemical properties of the antigen-binding pockets. Furthermore, the use of peptide 
display or small molecule libraries may directly identify and characterize peptides that 
differentially bind to HLA molecules that differ at risk-modulating positions, thereby revealing the 
essential pathogenic peptides and the mechanisms through which they evoke autoimmunity. 
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FIGURE LEGENDS 
Figure 1. Independently associated HLA loci to T1D. Each binary marker was tested for T1D 
association, using the imputed allelic dosage (between 0 and 2). In each panel, the horizontal 
dashed line marks p=5x10–8. Color gradient of the diamond indicates LD (r2) to the most 
strongly associated variant; the darkest shade is r2=1. A) The strongest associations were 
located in HLA-DRB1-DQA1-DQB1. The single strongest risk variant was alanine at DQβ1#57 
(OR=5.17; p=10-1090). See Supplementary Table 2 for unadjusted associations for all markers. 
B) Adjusting for all DRB1, DQA1, and DQB1 4-digit classical alleles, the strongest independent 
signals were in HLA-B. The strongest association was to B*39:06 (OR=6.64, p=10–75). C) 
Adjusting for HLA-DRB1-DQA1-DQB1 and HLA-B, the next associated variant was DPB1*04:02 
(OR=0.48, p=10–55). D) The final independent association was in HLA-A, led by glutamine at 
A#62 (OR=0.70, p=10–25). E) We found no residual independent association in the HLA-C or 
HLA-DPA1.  
 
Figure 2. Amino acid positions DQβ1#57, DRβ1#13, and DRβ1#71 independently drive 
T1D risk associated to the HLA-DRB1-DQA1-DQB1 locus. To identify each independently 
associated position, we used conditional haplotypic analysis by forward search, using the 
phased best-guess genotypes. In each panel, the dots mark amino acid positions along the 
gene (x-axis) and their log10 association p-values on the y-axis. The horizontal dashed line 
marks the log10 p-value of most strongly associated classical allele. The most strongly 
associated signals are circled. The colored arrows indicate positions that have been conditioned 
on. The most strongly associated position was DQβ1#57 (p=10–1355). Conditioning on it, 
DRβ1#13 was the next independently associated position (p=10–721), followed by DRβ1#71 
(p=10–95). Each position was much more strongly associated than the best classical allele 
(DQB1*03:02, DQA1*02:01, and DRB1*04:01, respectively). 
 
Figure 3. Amino acid residue effect sizes. Case (colored) and control (unfilled) frequencies, 
as well as unadjusted univariate odds ratio, of each residue, at DQβ1#57, DRβ1#13 and 
DRβ1#71. 
 
Figure 4. DQβ1#57, DRβ1#13 and DRβ1#71 are each located in the respective molecule’s 
peptide-binding groove. DRβ1#13 and #71 line the P4 pocket of the DR molecule.  
 
Figure 5. DQβ1#57, DRβ1#13 and DRβ1#71 explain over 90% of the phenotypic variance 
explained by the HLA-DRB1-DQA1-DQB1 locus. Assuming the liability threshold model and a 
global T1D prevalence of 0.4%, all haplotypes in HLA-DRB1-DQA1-DQB1 together explain 
29.6% of total phenotypic variance. DQβ1#57 alone explains 15.2% of the variance; the addition 
of DRβ1#13 and #71 increases the explained proportion to 26.9%. Therefore, these three amino 
acid positions together capture over 90% of the signal within HLA-DRB1-DQA1-DQB1. In 
contrast, variation in HLA-A, -B, and -DPB1 together explain approximately 4% of total variance. 
Genome-wide independently associated SNPs outside the HLA together explain about 9% of 
variance; rs678 (in the INS gene) and rs2476601 (in PTPN22) each explain 3.3% and 0.78%, 
respectively.  
 
Figure 6. Interactions between common HLA-DRB1-DQA1-DQB1 haplotypes lead to 
observed non-additive effects. We exhaustively tested the seven common haplotypes for 
pairwise interactions. Of the 21 possible pairs, eleven of them showed significant interactive 
effects. Along the perimeter, each segment represents one haplotype; red or blue color 
indicates risk or protective additive effect for each haplotype, respectively. Each arch connecting 
two haplotypes represents a significant interaction. Red indicates additional risk due to the 
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interaction beyond the additive effects; while blue indicates reduced risk (protection) due to the 
interaction beyond the additive effects. Thickness of the arches represents the effect size of the 
interaction (thicker red means larger risk while thicker blue means more protective.) See Tables 
2 and S9 for p-values and effect sizes of all pairwise haplotypic interactions
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Table 1. Haplotypes defined by DQβ1#57, DRβ1#13, and DRβ1#71 (control frequency > 0.1%). The three amino acid positions define 21 
common haplotypes. We list their multivariate ORs, frequencies in controls and cases, as well as classical 4-digit alleles tagged by each 
haplotype. See Supplementary Table 5B for multivariate ORs and p-values of all 31 haplotypes formed by DQβ1#57, DRβ1#13, and DRβ1#71. 
 
Haplotype OR CtrlFreq CaseFreq Classical HLA-DQB1 Alleles Classical HLA-DRB1 Alleles 
A-H-K 2.13 0.050 0.248 0201,0202,0302,0304,0305 0401,0409 
A-H-E 1.33 0.005 0.016 0201,0202,0302,0304,0305 0402,0437 
A-S-K (Ref) 1.00 0.145 0.332 0201,0202,0302,0304,0305 0301,0302,0304,1303 
A-H-R 0.89 0.054 0.107 0201,0202,0302,0304,0305 0403,0404,0405,0406,0407,0408,0410,0411 
A-S-E 0.53 0.001 0.001 0201,0202,0302,0304,0305 1102,1103,1301,1302,1304 
D-F-R 0.48 0.012 0.014 0301,0303,0401,0402,0503,0601,0602,0603 0101,0102,0901,1001 
A-F-R 0.43 0.001 0.001 0201,0202,0302,0304,0305 0101,0102,0901,1001 
S-R-R 0.37 0.008 0.007 0502,0504 1601,1602 
V-F-R 0.35 0.106 0.085 0501,0604,0609 0101,0102,0901,1001 
V-S-E 0.34 0.040 0.030 0501,0604,0609 1102,1103,1301,1302,1304 
D-G-R 0.32 0.039 0.029 0301,0303,0401,0402,0503,0601,0602,0603 0801-0806,1201,1202,1404,1415 
D-H-K 0.27 0.068 0.042 0301,0303,0401,0402,0503,0601,0602,0603 0401,0409 
V-F-E 0.24 0.013 0.006 0501,0604,0609 0103 
A-Y-R 0.18 0.103 0.043 0201,0202,0302,0304,0305 0701 
D-S-E 0.11 0.058 0.015 0301,0303,0401,0402,0503,0601,0602,0603 1102,1103,1301,1302,1304 
D-F-E 0.08 0.004 0.001 0301,0303,0401,0402,0503,0601,0602,0603 0103 
D-H-R 0.06 0.017 0.002 0301,0303,0401,0402,0503,0601,0602,0603 0403-0408,0410,0411 
D-S-K 0.06 0.010 0.001 0301,0303,0401,0402,0503,0601,0602,0603 0301,0302,0304,1303 
D-S-R 0.05 0.083 0.010 0301,0303,0401,0402,0503,0601,0602,0603 
1101,1104,1106,1108,1305,1401,1402,1405,
1406,1407 
D-Y-R 0.03 0.041 0.003 0301,0303,0401,0402,0503,0601,0602,0603 0701 
D-R-A 0.02 0.140 0.005 0301,0303,0401,0402,0503,0601,0602,0603 1501 
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Table 2. Pairwise haplotypic interactions in HLA-DRB1-DQA1-DQB1. The table shows, for each given pair of haplotypes, the fold 
change in odds ratio (from additive effect-only) due to interaction. The “amino acids” column/row denote the residues at DQβ1#57, 
DRβ1#13, and DRβ1#71 corresponding to each haplotype. For each pair, the p-value of the interaction term is shown in parenthesis. 
Cells in bold indicate interactions that are significant after Bonferroni correction (p < 0.05/21=0.0024). Cells with underlines indicate 
the known DR3/DR4 heterozygote effect. The odds ratio of a given diploid genotype is calculated as additivehaplotype1 x additivehaplotype2 
x interaction1,2 (see Supplementary Table 9).  
 
  
DRB1 15:01 07:01 04:04 04:01 04:01 03:01 01:01 
DQA1 01:02 02:01 03:01 03:01 03:01 05:01 01:01 
DQB1 06:02 02:02 03:02 03:02 03:01 02:01 05:01 
  
Amino acids D-R-A A-Y-R A-H-R A-H-K D-H-K A-S-K V-F-R 
DRB1 
Amino 
acids 
Additive OR 0.16 0.19 2.77 5.49 1.40 2.83 1.00 (Ref) DQA1 
DQB1 
01:01 
V-F-R 1.00 (Ref) 
0.14 2.32 0.71 2.16 1.95 1.04 
  
01:01 (0.004) (0.04) (0.19) (1.2 x 10
–4
) (7.7 x 10
–4
) (0.77) 
05:01       
  
  
03:01 
A-S-K  2.83 
0.09 2.24 2.12 1.96 0.32 
   05:01 (1.2 x 10
–5
) (0.03) (1.9 x 10
–4
) (1.2 x 10
–5
) (9.2 x 10
–11
) 
 02:01 
 
  
   
 04:01 
D-H-K 1.40 
0.26 4.78 0.23 0.48 
  
 
 03:01 (0.03) (1.1 x 10
–4
) (2.4 x 10
–6
) (1.1 x 10
–3
) 
 03:01   
   
 04:01 
A-H-K 5.49 
0.36 5.09 0.33 
  
  
 03:01 (0.03) (4.2 x 10
–5
) (3.5 x 10
–5
) 
 03:02   
  
 04:04 
A-H-R  2.77 
0.62 2.16 
  
   
 03:01 (0.03) (0.08) 
 03:02     
 07:01 
A-Y-R 0.19 
0.76 
  
    
 02:01 (0.74) 
 02:02   
 15:01 
D-R-A 0.16   
     
 01:02 
 06:02 
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ONLINE METHODS 
Sample collection 
The dataset was provided by the Type 1 Diabetes Genetics Consortium20, and consisted of (1) a 
UK case-control dataset (UK) and (2) a European family based dataset (Eur). All samples were 
collected after obtaining informed consent. The UK case-control dataset consisted of a total of 
16,086 samples (6,670 cases and 9,416 controls) from 3 collections: (1) cases from the UK-
GRID, (2) shared controls from the British 1958 Birth Cohort and (3) shared controls from Blood 
Services controls (data release February 4, 2012, hg18). The UK samples were collected from 
13 regions, listed in Supplementary Table 1. The European Family based dataset consisted of 
10,791 samples (5,571 affected children and 5,220 controls) from 2,699 European-ancestry 
families (data release January 30, 2013, hg18). All samples were genotyped on the 
ImmunoChip array. After quality control, 6,223 and 6,608 markers, respectively, were genotyped 
in the MHC region between 29 and 45Mb on Chromosome 6 in the two datasets. From the 
family data we constructed 1,662 pairs of pseudocase and pseudocontrol samples (see 
Supplementary Note). 
 
HLA Imputation 
We used SNP2HLA (default input parameters) to impute SNPs, amino acid residues, indels, 
and 2- and 4-digit classical alleles in eight HLA genes in the MHC between 29602876 and 
33268403bp on Chromosome 6. We used the reference panel provided by T1DGC, which 
included 5,225 European samples classical typed for HLA-A, B, C, DRB1, DQA1, DQB1, DPB1, 
and DPA1 4-digit alleles21,22. The imputed genotype dataset included 8,961 binary markers prior 
to frequency tresholding. For each marker and each individual, two types of output were 
produced: a phased best-guess genotype (e.g. “AA/AT/TT”); and a dosage, which accounts for 
imputation uncertainty and can be continuous between 0 (0 copies of the alternative allele) and 
2 (2 copies of the alternative allele). 
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We imputed the UK case-control dataset and European family dataset independently; within 
each set, cases and controls were imputed together to avoid disparity in imputation quality. 
4,604 and 5,125 SNPs in the MHC region were used for imputation in the UK and Eur datasets, 
respectively. After combining the UK and Eur datasets, we excluded a total of 344 binary 
markers due to allele missingness or rareness (allele frequency < 0.05%); we then removed 
individuals who carried the missing or rare alleles. The post-quality control final dataset 
consisted of 18,832 samples, including 8,095 cases (including 1,662 pseudo-cases) and 10,737 
controls (including 1,662 pseudo-controls). 
 
Statistical framework 
We test a given variant’s association to disease status using the logistic regression model: 
   (     )      ∑         
   
   
 ∑             
   
   
 
where variant xi may be an imputed dosage or the best-guess genotype for a SNP, classical 
allele, amino acid, or haplotype. β0 is the logistic regression intercept and β 1,j is the additive 
effects of allele j of variant xi. The number of alleles at each variant is m; for a binary variant 
(presence or absence of xi), m equals 2. The covariate yi,k denotes each region of sample 
collection (n=14). We included sex as a covariate z. β2 and  β3 are the effect sizes of the region 
and gender covariates, respectively.  
 
To account for population stratification, we included the region codes as covariates (see 
Supplementary Note). Samples from the Eur dataset were considered as the 14th region. To 
assess the statistical significance of a tested variant, we calculated the improvement of fit of the 
model containing the test variant over the null model (only region and gender covariates). We 
calculate the model improvement as deviance defined by 
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Δdeviancealt–null = -2ln(likelihoodalt/likelihoodnull), which follows a χ
2 distribution with m–1 degrees 
of freedom, from which we calculate the p-value. We considered p = 5x10-8 as the significance 
threshold.  
 
Analysis of amino acid positions  
To test amino acid effects within HLA-DRB1-DQA1-DQB1, we applied conditional haplotypic 
analysis. We tested each single amino acid position by first identifying the m amino acid 
residues occurring at that position, and partitioning all samples into m groups with identical 
residues at that position. We estimated the effect of each of the m groups using logistic 
regression model (including covariates as above), and assessed the significance of model 
improvement by Δdeviance compared to the null model, with m–1 degrees of freedom. This is 
equivalent to testing a single multi-allelic locus for association with m alleles. To test the effect 
of a second amino acid position while conditioning on the first, we further update the model to 
include all unique haplotypes created by residues at both positions. We then test whether the 
updated model improves upon the previous model based on Δdeviance, taking into 
consideration the increased degrees of freedom.  
 
Exhaustive test 
To ensure that the independently associated amino acids were not emerging only as the result 
of forward-search which might possibly converge on local minima, we exhaustively tested of all 
possible combinations of one, two, three, and four amino acid positions in HLA-DRB1, DQA1, 
and DQB1. For each number of amino acid combination, we select the best model based on 
Δdeviance from the null (gender and region covariates only). 
  
Haplotype-amino acid permutation analysis 
Given the polymorphic nature of the HLA genes and the strong effect sizes in the DRB1-DQA1-
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DQB1 locus, we wanted to assess whether the observed associations at DQβ1#57, DQβ1#13 
and DQβ1#71 could emerge by chance, due to these positions’ ability to tag classical alleles 
with different risks. To eliminate this possibility, we conducted a permutation test. In each 
permutation, for each of the three genes (e.g HLA-DQB1, -DRB1, and -DQA1) we preserved the 
sample’s case/control status and gender/region covariates. To preserve allelic associations, we 
preserved groups of samples with the same amino acid sequence (4-digit classical allele) at 
each gene. We then randomly reassigned the amino acid sequence corresponding to each 
classical allele in each permutation, and repeated the forward-search analysis. We repeated this 
permutation 10,000 times, each time selecting the combination of two, three, and four amino 
acid positions that produce the best model (as measured by deviance). If the amino acids were 
merely tagging the effects of certain haplotypes, the effects we observed in the real data would 
not be more significant compared to those generated from permutations. To obtain the 
permutation-based p-value, we calculate the proportion of permutated models that exceeds the 
goodness-of-fit of the best model in the unpermuted data. 
 
Testing for non-additivity and interactions 
We defined haplotypes across the HLA-DRB1-DQA1-DQB1 locus based on unique 
combinations of amino acid residues across the three genes. As non-additive effects can be 
observed only when sufficient numbers of homozygous individuals are present, we limited the 
interaction analysis to a subset of common haplotypes or classical alleles with frequencies 
greater than 5%. We excluded all individuals with one or more haplotypes that fell below this 
threshold.  
 
We constructed an interaction model, which included additive terms for each common haplotype 
and interaction terms between all possible pairs of common haplotypes. 
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where  is the interaction effect size. We determined the improvement in fit with each 
successive model by calculating the change in deviance, and used a significance threshold of p 
= 0.05/h, where h is the total number of interactive parameters added to the original additive 
model.  
 
HLA-DR3/DR4 classical allele interactions 
To characterize the DR3/DR4 interaction, we defined 12 interaction terms, where each term 
represents a potential interaction between a classical allele on the DR3 haplotype (DRB1*03:01, 
DQA1*05:01, DQB1*02:01) and a classical allele on the DR4 haplotype (DRB1*04:01 or 
DRB1*04:04, DQA1*03:01, DQB1*03:02). We only looked at trans interactions, since haplotype 
analyses already account for classical alleles that occur together in cis. We began with a null 
model that included additive effects for all haplotypes. Then, we individually tested each of the 
12 interaction terms by adding each term to the null model separately. Once again, we used the 
change in deviance to assess the improvement in fit, using p=0.05/21=2.4x10–3 as the threshold.  
 
Amino acid interaction analysis 
To determine whether amino acid positions can explain haplotypic interactions, we defined 
haplotypes across the DRB1-DQA1-DQB1 locus based on the 141 amino acid positions 
imputed in this locus. To ensure that a significant number of homozygous individuals were 
present, we excluded all amino acid residues with less than 5% frequency prior to creating the 
haplotypes. We also excluded any individual who had one or more amino acids that fell below 
this threshold.  
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We began with a null model that included additive effects for each amino acid haplotype. Then, 
for each pair of amino acid positions {q, r}, we added a set of nq x nr interaction terms, where 
each term specifies a trans interaction between one variant at each position, and np represents 
the total number of variants at position p. Each pair of amino acids was tested in a separate 
model, and we calculated the change in deviance to determine the improvement in fit. 
Monomorphic amino acid positions were excluded from this analysis, since they were constant 
across all individuals. 
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